Zoetis (ZTS) Total Current Liabilities (2012 - 2026)
Zoetis' (ZTS) quarterly Total Current Liabilities came in at $2.1 billion in Q1 2026, down 39.35% year-on-year from $3.4 billion in Q1 2025, and down 5.52% on a QoQ basis from $2.2 billion in Q4 2025.
Zoetis (ZTS) Total Current Liabilities (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 15 years of Total Current Liabilities data on file, last reported at $2.1 billion in Q1 2026.
- On a quarterly basis, Total Current Liabilities fell 39.35% year-over-year to $2.1 billion in Q1 2026; TTM through Mar 2026 was $2.1 billion, a 39.35% decrease from a year earlier, with the FY2025 full-year figure at $2.2 billion, down 36.31% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $2.1 billion, down from $2.2 billion in the prior quarter.
- Over the last five years, Total Current Liabilities for ZTS reached as high as $3.4 billion in Q4 2024 and fell as low as $1.6 billion in Q3 2023.
- Historically, Total Current Liabilities has averaged $2.4 billion across 5 years, with a median of $2.1 billion in 2026.
- Across the five-year window, Total Current Liabilities jumped 95.79% in 2022 and sank 44.17% in 2023, its largest moves.
- Year by year, Total Current Liabilities stood at $3.2 billion in 2022, then slumped by 40.35% to $1.9 billion in 2023, then jumped by 80.62% to $3.4 billion in 2024, then sank by 36.31% to $2.2 billion in 2025, then dropped by 5.52% to $2.1 billion in 2026.
- Per Business Quant data, the three most recent Total Current Liabilities figures were $2.1 billion in Q1 2026, $2.2 billion in Q4 2025, and $1.8 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 6.56 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.53 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 2.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 18.06 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 13.17 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 6.81 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 831.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.66 Bn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 215.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.05 Bn |
| Dec 31, 2025 | 2.17 Bn |
| Sep 30, 2025 | 1.81 Bn |
| Jun 30, 2025 | 3.37 Bn |
| Mar 31, 2025 | 3.39 Bn |
| Dec 31, 2024 | 3.41 Bn |
| Sep 30, 2024 | 1.70 Bn |
| Jun 30, 2024 | 1.80 Bn |
| Mar 31, 2024 | 1.91 Bn |
| Dec 31, 2023 | 1.89 Bn |
| Sep 30, 2023 | 1.61 Bn |
| Jun 30, 2023 | 1.77 Bn |
| Mar 31, 2023 | 1.92 Bn |
| Dec 31, 2022 | 3.17 Bn |
| Sep 30, 2022 | 2.88 Bn |
| Jun 30, 2022 | 3.05 Bn |
| Mar 31, 2022 | 3.03 Bn |
| Dec 31, 2021 | 1.80 Bn |
| Sep 30, 2021 | 1.47 Bn |
| Jun 30, 2021 | 2.09 Bn |